One of the most robustly campaigned and well-known drugs for treating COVID is Paxlovid. Yet the drug’s limited clinical studies and numerous drug interactions raise questions of safety for COVID patients.
Approved for Emergency Use Authorization (EUA) in December 2021 and promoted by the Food and Drug Administration (FDA), health officials, and politicians alike, Paxlovid is fast becoming the one-track drug for early COVID treatment.
Paxlovid’s EPIC-HR clinical trial, sponsored by Pfizer, revealed that those who took the drug were 89 percent less likely to develop severe COVID than those who took a placebo. Those who took Paxlovid also had lower quantities of the SARS-CoV-2 virus detected after five days of treatment….